PubMed HealthSearch

Biomedical subjects

H F Catania

Publications and source records attributed to H F Catania.

2 recordsLinked to original sources

Four years' experience with a clinical intervention program: cost avoidance and impact of a clinical coordinator.

Four years of data are reported on the drug cost avoidance and the net cost savings associated with a clinical pharmacy intervention program. In 1986 the pharmacy department at a 324-bed nonprofit community medical center began a clinical intervention program by adding one full-time equivalent for providing clinical services. A new clinical pharmacist position was created in 1988. A reorganization in 1989 resulted in further increases in staffing, including the creation of a clinical coordinator position to oversee the intervention program, and in administrative time. Staff pharmacists self-report a broad range of interventions on a clinical documentation form. During the period 1986-1989, monthly data on the number of types of interventions recommended, the percentage of recommendations accepted by the medical staff, and drug cost avoidance were tabulated. Cost avoidance was calculated by subtracting the cost of therapy ordered by the physician from the cost of therapy initiated as a result of the intervention. Net drug cost savings were calculated by subtracting from cost avoidance the cost of pharmacist time required for performing the interventions. The average number of interventions per month ranged from 170 in 1986 to 292 in 1990. During an 18-month period before the clinical coordinator was added, average monthly cost avoidance and net savings were $4932 and $3739, respectively. Average monthly cost avoidance increased to $6244 and savings to $4644 in a 12-month period after the clinical coordinator was added. A four-year study of a clinical intervention program showed that the dollar value and impact outlasted the initial success expected for such programs.

Administrative Personnel

Analyzing pharmacy charges using DRGs.

Pharmacy charges at a 316-bed community hospital were analyzed using diagnosis-related groups (DRGs). All patients admitted to the hospital between January 1, 1983, and August 31, 1983, were retrospectively categorized by DRG. For the 20 most expensive DRGs for the pharmacy department in terms of pharmacy charges, the following data were compiled: number of patients, total pharmacy charges, mean hospital and pharmacy charges per patient, mean length of stay, pharmacy charges as a percentage of hospital charges, and DRG distribution and total pharmacy charges by major diagnostic category ( MDC ). A total of 10,550 patients were assigned to 390 DRGs. For the 20 most expensive DRGs, the mean total pharmacy charges and number of patients per DRG were $83,457 and 140, respectively. DRG 107 (coronary bypass) and MDC 5 (diseases and disorders of the circulatory system) had the highest pharmacy charges in the respective DRG and MDC categories. Pharmacy charges as a percentage of hospital charges ranged from 4.1% to 32% for the 20 most expensive DRGs. While there appeared to be a direct relationship between high hospital charges and length of stay for the most expensive DRGs, there did not appear to be a direct relationship between these two measures and high pharmacy charges. Until hospitals have data on actual cost per case and on cost per DRG for each department, analysis of pharmacy charge data by DRG for establishing pharmacy priorities may be a reasonable approach.

California